Oxford Biomedica Quote more

Price: 2.45

Chg: 0.35

Chg %: 16.67%

Date: 16:57

Gene therapy specialist Oxford Biomedica has been awarded a significant grant to help improve its supply chain.

A UK consortium of companies won 7.7m of government funding in grants and loans, with the FTSE Fledgling company taking 7.1m of this as lead member.

The consortium has been awarded, subject to due diligence and final confirmation, a 2.4m grant, of which Oxford BioMedica will receive 1.8m, and a 5.3m loan to OXB repayable by March 2017.

Chief Executive Officer John Dawson said the award was given to the company in recognition of its potential to become a world-leader in Advanced Therapy Medicinal Product (ATMP) manufacture and supply chain expertise.

He said the funds will help the company, supported by the consortium, in its plans to develop its capability in serum-free, non-adherent manufacturing techniques and expand its proprietary manufacturing facility in Oxford to contain a third production suite and a state-of-the-art fill-and-finish operation.

See the rest here:
Oxford Biomedica wins significant government funding

Comments are closed.